New Bedford, MA, United States
New Bedford, MA, United States

Time filter

Source Type

Vera D.M.A.,University of the Sea | Haynes M.H.,University of New Mexico | Ball A.R.,Toxikon Corporation | Dai T.,Massachusetts General Hospital | And 9 more authors.
Photochemistry and Photobiology | Year: 2012

Conventional antimicrobial strategies have become increasingly ineffective due to the emergence of multidrug resistance among pathogenic microorganisms. The need to overcome these deficiencies has triggered the exploration of alternative treatments and unconventional approaches towards controlling microbial infections. Photodynamic therapy (PDT) was originally established as an anticancer modality and is currently used in the treatment of age-related macular degeneration. The concept of photodynamic inactivation requires cell exposure to light energy, typically wavelengths in the visible region that causes the excitation of photosensitizer molecules either exogenous or endogenous, which results in the production of reactive oxygen species (ROS). ROS produce cell inactivation and death through modification of intracellular components. The versatile characteristics of PDT prompted its investigation as an anti-infective discovery platform. Advances in understanding of microbial physiology have shed light on a series of pathways, and phenotypes that serve as putative targets for antimicrobial drug discovery. Investigations of these phenotypic elements in concert with PDT have been reported focused on multidrug efflux systems, biofilms, virulence and pathogenesis determinants. In many instances the results are promising but only preliminary and require further investigation. This review discusses the different antimicrobial PDT strategies and highlights the need for highly informative and comprehensive discovery approaches. In just 20 years antimicrobial photodynamic therapy (PDT) has emerged as a discovery and development platform inspiring a proliferation of light-based antimicrobial explorations worldwide. However, the potential for microbial resistance development using PDT remains under-investigated. Studies of resistance have been sporadic but they are rapidly increasing, with recent reports examining key elements of the microbial phenotype. These include multidrug efflux systems, biofilm, spore formation, virulence and pathogenicity determinants. The emerging consensus is that the effectiveness of PDT may be profoundly impacted by all these systems, but the exact mechanisms of these effects remain elusive. For example, an array of studies suggests that antimicrobial photosensitizers are substrates of multidrug efflux systems. An evolving antimicrobial discovery concept is based on the exploration of synergies between photosensitizers and small molecules efflux pump inhibitors. PS photosensitizer (red), EPI efflux pump inhibitor (green). © 2012 The American Society of Photobiology.


News Article | December 20, 2016
Site: marketersmedia.com

— The report “Biological Safety Testing Market by Application (Stem Cell, Blood, Gene Therapy), Product (Instruments, Services, Kits, Reagents), & Test (Bioburden, Endotoxin, Cell Line Authentication, Residual Contamination, Adventitious Agents) - Global Forecast to 2019”, report provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the global biologics safety testing market along with the estimates and forecasts of the revenue and market share analysis. The global biologics safety testing market was valued at $1,758.69 million in 2014. This market is expected to grow at a CAGR of 12.23% to reach $3,130.85 million in 2019. The global biologics safety testing market is segmented based on product, test, application, and geography. By product, the market is divided into instruments, kits & reagents, and services. Of these, the kits & reagents segment accounted for the largest share of the global biologics safety testing market in 2014. The application segments included in this report are blood & blood products, cellular & gene therapy products, stem cell products, tissues & tissue products, and vaccines and therapeutics. Of these, vaccines and therapeutics hold the highest share. By test, the market is segmented into adventitious agents detection tests, bioburden tests, cell line authentication and characterization tests, endotoxin tests, residual host contaminant detection tests, sterility testing, and other tests (efficacy tests, toxicity tests, stability tests). The geographic segments included in this report are Asia, Europe, North America, and the Rest of the World (RoW). The Asian segment is further divided into China, India, Japan, and the Rest of Asia. North America includes Canada and the U.S. The rapidly increasing pharmaceutical and biotechnology industries and increasing number of new biologics products launched will be the two most important growth drivers for this market in the forecast period (2014-2019). For instance, the number of new products launched annually witnessed a strong upward trend between 2003 and 2013. The number of new products launched in 2013 was 56, as compared to 29 in 2003. The biologics pipeline has increased by 155%, from 355 treatments in 2001 to 907 in 2012. A strong pharmaceutical product pipeline will aid the growth of the pharmaceutical and biotechnology industry, which is an important end user of biologics safety testing products. Moreover, increasing government support for the pharmaceutical and biotechnology industries will further boost the demand for biologics safety testing products. In 2013, the European Research Council awarded $830 million for life sciences research projects across Europe. A similar trend can be observed in Asia. For instance, beginning from 2014, the Indian government plans to invest up to $5 billion a year for the next five years to boost the biotechnology sector in the country and make it a $100-billion industry by 2025. This increases the purchasing power of major research institutes, which in turn is driving the market for biologics safety testing products. Major players in the biologics safety testing market include Charles River Laboratories International, Inc. (U.S.), Lonza Group (Switzerland), Sigma-Aldrich Corporation (U.S.), SGS SA (Switzerland), WuXi PharmaTech (Cayman), Inc. (China), Avance Biosciences, Inc. (U.S.), BSL Bioservice (Germany), Cytovance Biologics, Inc. (U.S.), Merck KGaA (Germany), and Toxikon Corporation (U.S.). For more information, please visit http://www.marketsandmarkets.com/Market-Reports/biologics-safety-testing-market-34624144.html


Zhong L.,Toxikon Corporation
Frontiers of Medicine in China | Year: 2013

This study aimed to modify a chronic ocular hypertension (OHT) rat model to screen for potential compounds to protect retinal ganglion cells (RGCs) from responding to increased intraocular pressure (IOP). A total of 266 rats were prepared and randomly grouped according to different time-points, namely, weeks 3, 8, 16, and 24. Rats were sedated and eye examination was performed to score as the corneal damage on a scale of 1 to 4. The OHT rat model was created via the injection of a hypertonic saline solution into the episcleral veins once weekly for two weeks. OHT was identified when the IOP at week 0 was ≥ 6 mmHg than that at week -2 for the same eye. Viable RGCs were labeled by injecting 4% FluoroGold. Rats were sacrificed, and the eyes were enucleated and fixed. The fixed retinas were dissected to prepare flat whole-mounts. The viable RGCs were visualized and imaged. The IOP (mean ± SD) was calculated, and data were analyzed by the paired t-test and one-way ANOVA. The OHT model was created in 234 of 266 rats (87.97%), whereas 32 rats (12.03%) were removed from the study because of the absence of IOP elevation (11.28%) and/or corneal damage scores over 4 (0.75%). IOP was elevated by as much as 81.35% for 24 weeks. The average IOP was (16.68 ± 0.98) mmHg in non-OHT eyes (n = 234), but was (27.95 ± 0.97) mmHg in OHTeyes (n = 234). Viable RGCs in the OHT eyes were significantly decreased in a time-dependent manner by 29.41%, 38.24%, 55.32%, and 59.30% at weeks 3, 8, 16, and 24, respectively, as compared to viable RGCs in the non-OHT eyes (P < 0.05). The OHT model was successfully created in 88% of the rats. The IOP in the OHT eyes was elevated by approximately 81% for 24 weeks. The number of viable RGCs was decreased by 59% of the rats in a time-dependent manner. The modified OHT model may provide an effective and reliable method for screening drugs to protect RGCs from glaucoma. © 2013 Higher Education Press and Springer-Verlag Berlin Heidelberg.


Lister L.,Toxikon Corporation
Medical Device and Diagnostic Industry | Year: 2010

Some of the elements of biocompatibility testing are discussed and avoiding problems while testing are explored. The test article is classified to be as cytotoxic if the vast majority of the cells are dead or dying. The animals are dosed at the highest concentration determined to not produce any irritation and any observation noted will be considered an allergenic response. Pyrogenicity testing assesses whether or not a test article has the ability to cause a fever-like response. Genotoxicity testing, consisting of the bacterial reverse mutation assay, also known as the Ames assay, evaluates the test article's ability to cause damage to DNA, genes, and chromosomes. In implantation testing, the test material is placed into the body of test animals such as rabbit, and the tissue chosen for implantation should be tissue that is most suitable for the test article.


Lister L.,Toxikon Corporation
Medical Device and Diagnostic Industry | Year: 2010

The medical device biocompatibility testing describes a few ways to avoid potential pitfalls that could delay a product launch is discussed. It is essential to follow strict testing protocol, don't waste valuable resources planning your own criteria. Due to the lack of easily obtainable information, an engineer or regulatory affairs officer may decide to design tests that will meet FDA requirements and ISO matrices. The best course of action is to contact a contract research organization (CRO) that specializes in biocompatibility testing and performs these tests according to good laboratory practices (GLPs). Careful consideration should be given to each test article to determine an appropriate approach to the testing. Be sure to start the process early enough to allow for thorough and complete testing. Communicate all details accurately; and, to be as up to date as possible on all requirements, consult other qualified professionals to provide expertise.


Hattan S.J.,SimulTOF Systems | Du J.,Toxikon Corporation | Parker K.C.,SimulTOF Systems
Analytical Chemistry | Year: 2015

We describe the construction and characterization of a novel membrane designed to allow proteins separated by gel electrophoresis (SDS-PAGE) to be detected as peptides by mass spectrometry in an efficient and comprehensive manner. The key attribute of the membrane is a bifunctional design that allows for the digestion of protein(s) and retention of the resulting peptides with minimal lateral diffusion. Silane chemistries are used to differentially treat the opposing surfaces of a glass filter paper to enable this unique capability. (Figure Presented). © 2015 American Chemical Society.


PubMed | Toxikon Corporation and SimulTOF Systems
Type: Journal Article | Journal: Analytical chemistry | Year: 2015

We describe the construction and characterization of a novel membrane designed to allow proteins separated by gel electrophoresis (SDS-PAGE) to be detected as peptides by mass spectrometry in an efficient and comprehensive manner. The key attribute of the membrane is a bifunctional design that allows for the digestion of protein(s) and retention of the resulting peptides with minimal lateral diffusion. Silane chemistries are used to differentially treat the opposing surfaces of a glass filter paper to enable this unique capability.


News Article | November 18, 2016
Site: www.newsmaker.com.au

Global Cell Banking Outsourcing market is expected to grow from $3.42 billion in 2015 to reach $10.67 billion by 2022 with a CAGR of 17.6%. Growing research in cell line development and advancements in cell preservation techniques are the key factors fostering the market growth. In addition, increasing awareness of stem cell therapies, growth in cell bank facilities around the world are some of the key factors influencing the market growth. On the other hand, differing legal and ethical issues among countries throughout collection of cells, and therapies costs are inhibiting the market growth. The stem cell banking leads the market globally with the biggest market share and is expected to grow with a high CAGR during the forecast period. The growth of this segment is attributed to growing number of cord blood banks, and services among countries. North America is anticipated to hold the largest share in global market due to increasing demand from U.S. Asia Pacific is expected to witness huge growth due to encouraging government schemes and growing adoption of cell therapies. Some of the key players in global cell banking outsourcing market include CordLife, Cleancells, Charles River Laboratories, BSL Bioservice, BioReliance, BioOutsource/Sartorius, Covance, LifeCell International Pvt. Ltd., Goodwin Biotechnology Inc., GlobalStem Inc., Cryo-Cell International Inc., Cryobanks International India, Lonza, PX’Therapeutics SA, Wuxi Apptec, Tran-Scell Biologics Pvt. Ltd., Toxikon Corporation, Texcell, SGS Life Sciences, and Reliance Life Sciences. Regions Covered:  • North America  o US  o Canada  o Mexico  • Europe  o Germany  o France  o Italy  o UK  o Spain  o Rest of Europe  • Asia Pacific  o Japan  o China  o India  o Australia  o New Zealand  o Rest of Asia Pacific  • Rest of the World  o Middle East  o Brazil  o Argentina  o South Africa  o Egypt What our report offers:  - Market share assessments for the regional and country level segments  - Market share analysis of the top industry players  - Strategic recommendations for the new entrants  - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets  - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)  - Strategic recommendations in key business segments based on the market estimations  - Competitive landscaping mapping the key common trends  - Company profiling with detailed strategies, financials, and recent developments  - Supply chain trends mapping the latest technological advancements About Us Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.


News Article | November 3, 2016
Site: marketersmedia.com

— Growing research in cell line development and advancements in cell preservation techniques are the key factors fostering the market growth. In addition, increasing awareness of stem cell therapies, growth in cell bank facilities around the world are some of the key factors influencing the market growth. On the other hand, differing legal and ethical issues among countries throughout collection of cells, and therapies costs are inhibiting the market growth. The stem cell banking leads the market globally with the biggest market share and is expected to grow with a high CAGR during the forecast period. The growth of this segment is attributed to growing number of cord blood banks, and services among countries. North America is anticipated to hold the largest share in global market due to increasing demand from U.S. Asia Pacific is expected to witness huge growth due to encouraging government schemes and growing adoption of cell therapies. Some of the key players in global cell banking outsourcing market include CordLife, Cleancells, Charles River Laboratories, BSL Bioservice, BioReliance, BioOutsource/Sartorius, Covance, LifeCell International Pvt. Ltd., Goodwin Biotechnology Inc., GlobalStem Inc., Cryo-Cell International Inc., Cryobanks International India, Lonza, PX’Therapeutics SA, Wuxi Apptec, Tran-Scell Biologics Pvt. Ltd., Toxikon Corporation, Texcell, SGS Life Sciences, and Reliance Life Sciences. Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK o Spain o Rest of Europe • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements About Stratistics MRC We offer wide spectrum of research and consulting services with in-depth knowledge of different industries. We are known for customized research services, consulting services and Full Time Equivalent (FTE) services in the research world. We explore the market trends and draw our insights with valid assessments and analytical views. We use advanced techniques and tools among the quantitative and qualitative methodologies to identify the market trends. Our research reports and publications are routed to help our clients to design their business models and enhance their business growth in the competitive market scenario. We have a strong team with hand-picked consultants including project managers, implementers, industry experts, researchers, research evaluators and analysts with years of experience in delivering the complex projects. For more information, please visit http://www.strategymrc.com/


News Article | November 22, 2016
Site: www.newsmaker.com.au

According to Stratistics MRC, the Global Cell Banking Outsourcing market is expected to grow from $3.42 billion in 2015 to reach $10.67 billion by 2022 with a CAGR of 17.6%. Growing research in cell line development and advancements in cell preservation techniques are the key factors fostering the market growth. In addition, increasing awareness of stem cell therapies, growth in cell bank facilities around the world are some of the key factors influencing the market growth. On the other hand, differing legal and ethical issues among countries throughout collection of cells, and therapies costs are inhibiting the market growth. Access the complete report at: http://www.strategymrc.com/report/cell-banking-outsourcing-market The stem cell banking leads the market globally with the biggest market share and is expected to grow with a high CAGR during the forecast period. The growth of this segment is attributed to growing number of cord blood banks, and services among countries. North America is anticipated to hold the largest share in global market due to increasing demand from U.S. Asia Pacific is expected to witness huge growth due to encouraging government schemes and growing adoption of cell therapies. Some of the key players in global cell banking outsourcing market include CordLife, Cleancells, Charles River Laboratories, BSL Bioservice, BioReliance, BioOutsource/Sartorius, Covance, LifeCell International Pvt. Ltd., Goodwin Biotechnology Inc., GlobalStem Inc., Cryo-Cell International Inc., Cryobanks International India, Lonza, PX’Therapeutics SA, Wuxi Apptec, Tran-Scell Biologics Pvt. Ltd., Toxikon Corporation, Texcell, SGS Life Sciences, and Reliance Life Sciences. Request for a sample at: http://www.strategymrc.com/report/cell-banking-outsourcing-market Phases Covered: • Characterization • Preparation • Storage • Testing o Viral Cell Bank Safety Testing o Microbial Cell Bank Safety Testing o Gene Expression Testing o Karyology Testing o Gene Sequencing Testing Bank Types Covered: • Master Cell Banking • Viral Cell Banking • Working Cell Banking Cell Types Covered: • Stem Cell Banking o IPS Stem Cell Banking o Embryonic Cell Banking o Dental Stem Cell Banking o Adult Stem Cell Banking o Cord Cell Banking • Non-Stem Cell Banking Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK  o Spain      o Rest of Europe  • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements

Loading Toxikon Corporation collaborators
Loading Toxikon Corporation collaborators